Neurocrine Biosciences is dedicated to discovering and developing life-changing treatments for patients with debilitating neurological, psychiatric, endocrine, and immunological disorders. Founded in 1992 by scientists Wylie Vale and Lawrence Steinman, the company's mission is rooted in relieving suffering for people with great unmet medical needs.
With over 30 years of research, Neurocrine has developed FDA-approved treatments for conditions such as tardive dyskinesia, Huntington’s disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company continues to advance a robust pipeline of investigational therapies, driven by deep scientific understanding and tenacity in drug development.
Core values of passion, integrity, collaboration, innovation, and tenacity guide the organization as it pursues groundbreaking science to transform patient care in rare and under-addressed diseases.
